Gb004
WebMay 1, 2024 · GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with protective roles at the epithelial layer of the inflamed gut ... WebMar 4, 2024 · Danese et al recently presented a phase 1b study exploring the safety, tolerability, and pharmacological properties of GB004 in active UC. 9 In this double-blind, placebo-controlled trial, 34 patients were randomised 2:1 to receive oral GB004 120 mg or placebo once-daily for 28 days. The drug was well tolerated.
Gb004
Did you know?
WebSep 15, 2024 · Drug: GB004 Study Type Interventional Enrollment (Actual) 236 Phase Phase 2 Contacts and Locations This section provides the contact details for those conducting the study, and information on where this study is being conducted. Study Locations Georgia Tbilisi, Georgia, 0160 LTD Aversi Clinic Tbilisi, Georgia, 0160 WebJan 15, 2024 · GB004 is a small-molecule prolyl hydroxylase inhibitor that stabilises hypoxia-inducible factors (HIF-1α), key transcription factors involved in the protective cellular …
WebSearch Results A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) Study Purpose A 2-part study, comprising of a 36-week placebo-controlled period and a 24-week open-label extension period, to assess the efficacy and safety of 2 dose regimens of GB004 when added to background UC therapy of 5-aminosalicylate (5-ASA) with or … WebWe are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, …
WebJul 8, 2024 · Details for presentations related to GB004, an oral, gut-target HIF-1α stabilizer, are as follows: Digital Oral Presentation Title: Target Engagement and … WebGB004 is a small molecule prolyl hydroxylase inhibitor (PHDi) that stabilizes hypoxia inducible factors (HIF1-α), key transcription factors involved in the protective cellular …
WebGB004, a selective stabilizer HIF-1 alpha, is being developed for the treatment of inflammatory bowel disease. HIF-1 alpha is involved in mucosal wound healing and the reduction of inflammation in the gastrointestinal tract. Aerpio has completed a single ascending dose clinical trial of GB004 in healthy volunteers and has initiated a multiple ...
WebNov 10, 2024 · credits. released November 10, 2024. «GB004» — an b2b album by heroes of Russian dance music, co-curators of the Get Busy label: the duo of Ilsur Kasa and Mark Griboyedov Yung Acid and Винер. The release is rolling, loud and aggressive: immediately pushing the tempo up to 150 bpm, it doesn't leave a chance to organize your thoughts. ron y hermioneWebOct 12, 2024 · Gossamer Bio (NASDAQ:GOSS) has announced new data from GB004's Phase 1b study, on the reduction of fecal calprotectin, an inflammatory biomarker in … ron yantho realtorWebJan 15, 2024 · GB004 was selected based on its gut-targeted profile to limit systemic on-target effects associated with HIF-α stabilisation. GB004 is in clinical development for the … ron yanish rochester mnWeb16 hours ago · About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features NFL Sunday Ticket … ron y hermione besoWebOct 31, 2024 · GB004 was licensed from Aerpio Pharmaceuticals in 2024. In addition to $35 million covering two upfront payments, Gossamer is potentially obligated to pay out approval and sales milestones ... ron yarwood attorneyWebGB004: Oral HIF-1α Stabilizer for Inflammatory Bowel Disease (IBD) Primary endpoint week 12 topline data from the Phase 2 SHIFT-UC study in patients with mild-to-moderate ulcerative colitis (UC) are expected in the second quarter of 2024. ron yacoub miamiWebKnow about technical details of GB004 like: chemical name, chemistry structure, formulation, uses, toxicity, action, side effects and more at Pharmacompass.com. ron yaffe